Advanced Ovarian Cancer: Triplet Chemotherapy-Immunotherapy Combinations
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
AGO-OVER 17 BOOST Phase III Trial Results
- November 18, 2022
On November 4, 2022, researchers led by Jacobus Pfisterer from Arbeitsgemeinschaft Gynaekologische Onkologie published AGO-OVER 17 BOOST/GINECO OV118/ENGOT Ov-15 Phase III results in the Journal of Clinical Oncology, evaluating extended bevacizumab duration in first-line ovarian cancer treatment.
Trial Design
Patient Population: Stage IIB-IV advanced epithelial ovarian cancer (n=927)
Treatment Arms:
- Paclitaxel 175 mg/m² + Carboplatin + Bevacizumab 15 mg/kg for 15 months (n=469)
- Paclitaxel 175 mg/m² + Carboplatin + Bevacizumab 15 mg/kg for 30 months (n=458)
Primary Endpoint: Progression-free survival
Key Results
Progression-Free Survival Median:
- 15-month bevacizumab: 24.2 months
- 30-month bevacizumab: 26.0 months
- No significant difference
Overall Survival: No significant difference between groups
Safety Profile
Grade 3-4 adverse events: 29% (15-month group) vs 34% (30-month group), consistent with established safety profile.
Clinical Conclusions
Extended bevacizumab beyond 15 months does not provide additional progression-free or overall survival benefit in first-line advanced ovarian cancer treatment.
Data Source
https://ascopubs.org/doi/abs/10.1200/JCO.22.01010
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4